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ies, 432 symptom concepts (range 7-33, M= 16.6 [SD] 6.4) were elicited. Each sample 
was divided into quartiles based on the chronology of individual interviews. Study 
results (i.e., patient reports) were then reviewed to determine the interview number 
and quartile in which each concept was first elicited. Results: Analysis showed 
that 84.0% (n= 363), 92.4% (n= 399), 97.2% (n= 420), and 99.3% (n= 429) of all elicited 
concepts had emerged by the tenth, fifteenth, twentieth, and twenty-fifth inter-
view, respectively. Less than 1% (n= 3) of concepts emerged after the 25thinterview 
in samples with > 25 subjects. ConClusions: While a variety of factors inform 
sample size decisions in concept elicitation interview studies, this analysis sug-
gests that researchers can reasonably expect to elicit 95% to 100% of the targeted 
disease-related symptoms-level concepts, and thus achieve saturation, through the 
conduct of 20 to 25 interviews.
PRM133
ExPloRing thE REal WoRld sEtting of ChRoniC idioPathiC URtiCaRia 
and PhysiCian attitUdEs toWaRds it in thE Us
Gabriel S1, Herrera V2, Hoskin B3, Anderson P3, Karagiannis T4
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharmaceuticals, East 
Hanover, NJ, USA, 3Adelphi Real World, Macclesfield, MA, USA, 4Jefferson School of Population 
Health for Novartis Pharmaceuticals, East Hanover, NJ, USA
oBJeCtiVes: To describe the methodology of a real-world, cross-sectional survey 
of Chronic Idiopathic Urticaria (CIU) in the US, outlining collection of patient-
level data from both physicians and their patients as well as physician attitudi-
nal data. MetHoDs: The survey, conducted by Adelphi between November 2014 
and March 2015, incorporates Physician Interviews, Patient Record Forms (PRFs) 
completed by physicians, and Patient Self-Completion Forms (PSCs). Physicians 
provide data regarding current clinical practice, CIU history and progression, trig-
gers, continuous/intermittent symptoms, affected body sites, severity and treat-
ment. Patients provide information regarding their disease experience, sleep 
quality (Jenkins questionnaire), effects on daily/working life (Work Productivity 
and Activity Index) and satisfaction with treatment. Physician interviews include 
number of CIU patients managed, tests used to aid diagnosis, circumstances in 
which systemic and biologic therapy are used, and criteria for determining sever-
ity. Eligible physicians (Allergists and Dermatologists) each provided PRFs for 4 
non-refractory and 6 refractory patients. All patients were invited to take part 
anonymously in the self-completion exercise but this was not mandatory. Ethical 
approval was obtained. Results: The target sample is 100 physicians providing 
information on approximately 1000 CIU patients. While patient specific results are 
anticipated to be available from Q2 2015, early physician interview results (n= 5) 
suggest that diagnostic tests performed by up to 80% of specialists include com-
plete blood count, liver tests and anti-thyroglobulin/anti-thyroperoxidase antibody 
tests. The most important factors in determining CIU severity are frequency of 
symptomatic period and impact on quality of life. All of the physicians indicate 
being comfortable prescribing biologics for CIU patients and 4 out of 5 suggest 
they are suitable for 25-33% of their CIU patients. ConClusions: To date limited 
data are available on real world experience of CIU and this cross-sectional survey 
is providing a unique insight into the continuum of care for patients experiencing 
this distressing condition.
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oBJeCtiVes: This study examines comparators used for biologic Rheumatoid 
Arthritis (RA) drugs, both Tumor Necrosis Factor (TNF) drugs and Disease-
Modifying, Anti-Rheumatic Drugs (DMARDs), and the decision compared to the 
European label. The change in comparator categories for RA drugs over time is also 
assessed. MetHoDs: This research highlights RA Health Technology Assessments 
(HTAs), published from 2005 – 2014, from NICE, SMC, HIS, HAS, and IQWiG. (The 
G-BA did not review RA during this time frame.) Comparators were split into two 
non-mutually-exclusive categories: comparators that included methotrexate, and 
comparators that included DMARDs. Comparators that included methotrexate were 
separated into: methotrexate alone, or methotrexate with other drugs. Comparators 
that included DMARDs were split into: biologics alone, biologics plus methotrexate, 
and conventional DMARDs (no biologics). By matching on indication and time, and 
restricting against the European label, HTA decisions were determined to be either: 
Recommend, Recommend With Restrictions (RWR), Do Not Recommend (DNR), or 
No Decision. Results: The sample included 77 reviews. Twenty-two reviews used 
methotrexate in combination with biologic drugs as comparators. Of these, 13 (59%) 
received a Recommend, six (27%) received RWR, and three (14%) were DNR. The fre-
quency of the use of biologics (alone or in combination) as comparators increased 
each year between 2006, with 14% (1/7), and 2009, with 60% (3/5). In 2009, one (20%) 
of the five reviews was the first to use a biologic exclusively as a comparator, and 
received a decision of Recommend. In 2013, two (13%) of the 15 reviews used biolog-
ics only, and received No Decision. In 2014, all two (100%) of the reviews used bio-
logics alone as comparators, with one receiving a decision of Recommend, and the 
other RWR. ConClusions: While the categories of comparators used in RA varied 
over time, the increased use of biologics in recent years illustrates a steady trend.
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oBJeCtiVes: Survey response rates continue to decline across all modes of admin-
istration for public, private, and government organizations conducting survey 
research. This review examines response rates (RR) for direct-to-patient survey 
studies in health economics and outcomes research (HEOR). MetHoDs: RR was 
scores. ConClusions: The K-means CA method appeared optimal in healthcare 
claims data with highly skewed cost information when taking into account both 
change of cost patterns and sample size in smallest cluster.
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oBJeCtiVes: Signorovitch (2010) describes MAIC that focuses on matching one 
study with individual patient data (IPD) to the covariates in one study with aggre-
gated data (AGR). However in most scenarios there are likely to be multiple studies 
with IPD and AGR that need to be included in the Indirect Comparison. In addition 
it may be necessary to extend the network of treatments to include more than the 
two treatments with a single comparator. MetHoDs: We propose a number of 
potential solutions for including multiple studies and multiple treatments in the 
MAIC and assess these using simulations with the weighting methods proposed by 
Signorovitch(2010) as well as with Entropy Balancing Hainmueller (2012) Results: 
When multiple IPD studies exist then MAIC can be conducted if you consider a)
Pooling IPD studies, into one large study and match against the AGR study or b) 
matching each IPD study against the AGR study. For multiple AGR studies then the 
IPD data can be matched against a) just one AGR study, b) the average patient char-
acteristics from the AGR studies, c) the average mean and variances from the AGR 
studies or d) the distribution of patient characteristics using MCMC from the AGR 
studies. To apply a MAIC in Networks involving multiple studies the choice of study 
to match on could be an issue so it is important that the assumptions surrounding 
the NMA are tested, and only if there is no evidence to suggest inconsistency and 
heterogeneity within the Network, should IPD studies be added to the Network via 
an MAIC. ConClusions: MAIC can be applied in scenarios where you have multi-
ple studies and treatments if the existing Network satisfies the assumptions around 
heterogeneity and inconsistency required when performing Network Meta-Analysis.
PRM131
ClassifiCation tREE analysis of thE likElihood of CloPidogREl 
tREatMEnt in a CohoRt of PatiEnts With syMPtoMatiC PERiPhERal 
aRtERy disEasE
Reed Chase M.1, Friedman H.2, Navaratnam P.2, Heithoff K.1, Simpson Jr. RJ3
1Merck & Co., Kenilworth, NJ, USA, 2DataMed Solutions LLC, New York City, NY, USA, 3University 
of North Carolina, Chapel Hill, NC, USA
oBJeCtiVes: We evaluated whether treatment initiation of clopidogrel among 
symptomatic peripheral artery disease (SPAD) was impacted by post-stenting 
prevention of thromboembolic complications in patients with comorbid coro-
nary artery disease (CAD), in spite of primary use as secondary prevention in 
SPAD. MetHoDs: Patient records from Jan 1, 2006 through June 30, 2010 were 
extracted from the MarketScan Commercial Claims and Encounters database. 
Patients met inclusion criteria if they had a record of SPAD but were excluded if 
they had stroke/TIA or contraindications to anti-platelet therapy. Claims identi-
fied 1 year prior to and 3 years post-earliest record of SPAD were included in the 
analysis. Clopidogrel initiators ± 90 days from the index date were identified. A 
classification tree model was created with the outcome being the likelihood of 
treatment initiation with clopidogrel controlling for select baseline covariates. 
The model used the misclassification criterion, required a minimum of 50 obser-
vations/leaf and a maximum of 2 branches/ node. As a comparison, a stepwise 
logistic regression model was also constructed. Results: Of 16,377 SPAD patients, 
5,164 (32%) initiated clopidogrel treatment. The output model had 18 leaves, rang-
ing from 0.3%-53.4% of the population. The most important variables were PAD 
outpatient payment (importance score (IS) = 1), CAD [IS= 0.89], pre-index percu-
taneous coronary intervention (PCI) [IS= 0.46] and pre-index statin use (IS= 0.33). 
Similar results were obtained with the logistic regression model. The highest prob-
ability leaf for clopidogrel initiation (74.6%; 2.5% of the population) and included 
patients with low PAD outpatient payment (< $145), comorbid CAD, pre-index PCI 
and ≥ 1 pre-index all-cause inpatient admission. ConClusions: Our results show 
clopidogrel use in SPAD patients may be impacted by the presence of comorbid 
CAD and/or prior PCI use. When evaluating the effectiveness of clopidogrel for 
SPAD-related outcomes, comorbid CAD and/or PCI use should be considered as 
confounding variables.
REsEaRCh on MEthods – study design
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oBJeCtiVes: As an indicator that concept elicitation study results are robust and 
trustworthy, the value of demonstrating saturation (i.e., the point at which no new 
information is gained from conducting additional interviews) in qualitative research 
is widely accepted. Nevertheless, there is little empirical evidence to guide research-
ers in making a prioridecisions regarding sample size in such studies. This study 
sought to assist in providing such evidence. MetHoDs: A retrospective analysis of 
saturation results from n= 26 concept elicitation studies completed between 2006 
and 2013 was conducted. Studies included a total of n= 633 subjects (57% female), 
representing a spectrum of therapeutic categories, ages (M= 47.5 [SD] 17.2 years), eth-
nicities (33% non-Caucasian), and education status (25.8% with high school degree 
or less). The vast majority of the interviews were conducted in the US (99.2%) across 
25 states. Study sample sizes ranged from 10-43 (M= 20.9 [SD] 8.1). Across all stud-
